IBDEI2LX ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,683,0)
 ;;=SLEEP DISORDERS^32^58
 ;;^UTILITY(U,$J,358.4,684,0)
 ;;=SUBSTANCE ABUSE-ALCOHOL^35^58
 ;;^UTILITY(U,$J,358.4,685,0)
 ;;=SUBSTANCE ABUSE-AMPHETAMINE^36^58
 ;;^UTILITY(U,$J,358.4,686,0)
 ;;=SUBSTANCE ABUSE-CANNABIS^38^58
 ;;^UTILITY(U,$J,358.4,687,0)
 ;;=SUBSTANCE ABUSE-HALLUCINOGEN^40^58
 ;;^UTILITY(U,$J,358.4,688,0)
 ;;=SUBSTANCE ABUSE-OPIOID^42^58
 ;;^UTILITY(U,$J,358.4,689,0)
 ;;=SUBSTANCE ABUSE-PSYCHOACTIVE DRUGS^43^58
 ;;^UTILITY(U,$J,358.4,690,0)
 ;;=SUBSTANCE ABUSE-SEDATIVE/HYPNOTIC^44^58
 ;;^UTILITY(U,$J,358.4,691,0)
 ;;=SUBSTANCE ABUSE-TOBACCO^45^58
 ;;^UTILITY(U,$J,358.4,692,0)
 ;;=SUBSTANCE ABUSE-COCAINE^39^58
 ;;^UTILITY(U,$J,358.4,693,0)
 ;;=TRAUMA/STRESSOR-RELATED DISORDERS^46^58
 ;;^UTILITY(U,$J,358.4,694,0)
 ;;=SUBSTANCE ABUSE-INHALANT^41^58
 ;;^UTILITY(U,$J,358.4,695,0)
 ;;=INTELLECTUAL DISABILITIES^19^58
 ;;^UTILITY(U,$J,358.4,696,0)
 ;;=CLINICAL RESEARCH PROGRAM^5^58
 ;;^UTILITY(U,$J,358.4,697,0)
 ;;=SOMATOFORM DISORDERS^34^58
 ;;^UTILITY(U,$J,358.4,698,0)
 ;;=DISRUPTIVE,IMPULSE-CONTROL DISORDERS^11^58
 ;;^UTILITY(U,$J,358.4,699,0)
 ;;=ELIMINATION DISORDERS^15^58
 ;;^UTILITY(U,$J,358.4,700,0)
 ;;=GAMBLING DISORDER^16^58
 ;;^UTILITY(U,$J,358.4,701,0)
 ;;=OTHER MENTAL DISORDERS^24^58
 ;;^UTILITY(U,$J,358.4,702,0)
 ;;=NEURODEVELOPMENTAL DISORDERS^21^58
 ;;^UTILITY(U,$J,358.4,703,0)
 ;;=SUBSTANCE ABUSE-CAFFEINE^37^58
 ;;^UTILITY(U,$J,358.4,704,0)
 ;;=SPECIAL SERVICES^7^59
 ;;^UTILITY(U,$J,358.4,705,0)
 ;;=TREATMENT^8^59
 ;;^UTILITY(U,$J,358.4,706,0)
 ;;=MISCELLANEOUS^5^59
 ;;^UTILITY(U,$J,358.4,707,0)
 ;;=IMMUNIZATIONS^3^59
 ;;^UTILITY(U,$J,358.4,708,0)
 ;;=CHEMO ADMINISTRATION^1^59
 ;;^UTILITY(U,$J,358.4,709,0)
 ;;=CHEMO DRUGS^2^59
 ;;^UTILITY(U,$J,358.4,710,0)
 ;;=OTHER DRUGS^6^59
 ;;^UTILITY(U,$J,358.4,711,0)
 ;;=MGMT L/T ANTICOAG TX^4^59
 ;;^UTILITY(U,$J,358.4,712,0)
 ;;=NEW PATIENT^2^60
 ;;^UTILITY(U,$J,358.4,713,0)
 ;;=ESTABLISHED PATIENT^1^60
 ;;^UTILITY(U,$J,358.4,714,0)
 ;;=CONSULTATIONS^3^60
 ;;^UTILITY(U,$J,358.4,715,0)
 ;;=POST OP^4^60
 ;;^UTILITY(U,$J,358.4,716,0)
 ;;=ANEMIA^1^61
 ;;^UTILITY(U,$J,358.4,717,0)
 ;;=BREAST & GYN NEOPLASMS^2^61
 ;;^UTILITY(U,$J,358.4,718,0)
 ;;=COAGULATION DISORDERS^3^61
 ;;^UTILITY(U,$J,358.4,719,0)
 ;;=COUNSELING & SCREENING^4^61
 ;;^UTILITY(U,$J,358.4,720,0)
 ;;=GENITOURINARY NEOPLASMS^5^61
 ;;^UTILITY(U,$J,358.4,721,0)
 ;;=GI CANCER^6^61
 ;;^UTILITY(U,$J,358.4,722,0)
 ;;=HEAD/NECK/LUNG CANCER^7^61
 ;;^UTILITY(U,$J,358.4,723,0)
 ;;=HEMOGLOBINOPATHIES^8^61
 ;;^UTILITY(U,$J,358.4,724,0)
 ;;=LYMPHOID NEOPLASMS^9^61
 ;;^UTILITY(U,$J,358.4,725,0)
 ;;=METASTATIC SITES^10^61
 ;;^UTILITY(U,$J,358.4,726,0)
 ;;=MISC. NEOPLASMS^11^61
 ;;^UTILITY(U,$J,358.4,727,0)
 ;;=MYELOID NEOPLASMS/DISORDERS^12^61
 ;;^UTILITY(U,$J,358.4,728,0)
 ;;=PERSONAL HX OF CANCER^14^61
 ;;^UTILITY(U,$J,358.4,729,0)
 ;;=OTHER^13^61
 ;;^UTILITY(U,$J,358.4,730,0)
 ;;=HOSPICE CARE SUPERVISION^1^62
 ;;^UTILITY(U,$J,358.4,731,0)
 ;;=PROLONGED SERVICES^2^62
 ;;^UTILITY(U,$J,358.4,732,0)
 ;;=INPATIENT CONSULTATIONS^1^63
 ;;^UTILITY(U,$J,358.4,733,0)
 ;;=INITIAL INPATIENT CARE^2^63
 ;;^UTILITY(U,$J,358.4,734,0)
 ;;=SUBSEQUENT INPATIENT CARE^3^63
 ;;^UTILITY(U,$J,358.4,735,0)
 ;;=DISCHARGE/PRONOUNCEMENT^4^63
 ;;^UTILITY(U,$J,358.4,736,0)
 ;;=NH INITIAL INPATIENT CARE^5^63
 ;;^UTILITY(U,$J,358.4,737,0)
 ;;=NH SUBSEQUENT INPATIENT CARE^6^63
 ;;^UTILITY(U,$J,358.4,738,0)
 ;;=NH DISCHARGE/PRONOUNCEMENT^7^63
 ;;^UTILITY(U,$J,358.4,739,0)
 ;;=NEOPLASMS^8^64
 ;;^UTILITY(U,$J,358.4,740,0)
 ;;=CARDIOVASCULAR DISORDERS^2^64
 ;;^UTILITY(U,$J,358.4,741,0)
 ;;=MENTAL HEALTH^7^64
